Trials / Not Yet Recruiting
Not Yet RecruitingNCT06669143
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
The Efficacy and Safety of Zanubutinib-based for Post-remission Maintenance in Patients With Diffuse Large B-cell Lymphoma Who Are Intolerant to Intense First-line Chemotherapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | 160 mg bid, po, day 1-21, a maximum of 2 years. |
| DRUG | Lenalidomide | 25 mg qd, po, day 1-10, a maximum of 2 years. |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2026-11-01
- Completion
- 2027-12-01
- First posted
- 2024-11-01
- Last updated
- 2024-11-01
Source: ClinicalTrials.gov record NCT06669143. Inclusion in this directory is not an endorsement.